Acquired by 3M in October 2006, Brontes changes the way dentists treat their patients by enabling practitioners to perform ImpressionFreeTM dentistry. Brontes’ 3D intraoral imaging technology quickly and painlessly scans both arches of the mouth, thereby replacing the antiquated dental impression process. The company was founded in 2003 based on the research of Dr. János Rohály, Professor Douglas Hart and two graduate students from the Department of Mechanical Engineering at the Massachusetts Institute of Technology, Eric Paley and Micah Rosenbloom.
Founded in January 2008, Calxeda brings unseen performance density to the data center on a very attractive power foot print by leveraging ultra-low power processors as used on mobile phones, as a foundation for its revolutionary technology. Calxeda will make it possible for data center managers to increase the density of their computer resources while significantly reduce need for power, space and cooling. At the same time, Calxeda technology will contribute to the reduction of the CO2 footprint of the data center in a significant way. More about Calxeda can be found at www.calxeda.com.
ChiL was acquired by International Rectifier in February 2011 and is a mixed-signal fabless semiconductor company focusing on delivering intelligent, high efficiency digital power products into the computing industry.
A pioneer in developing and implementing next-generation lighting solutions, Digital Lumens is taking a game-changing approach to the industrial lighting market. With the introduction of the first Intelligent Lighting System, the company is combining LEDs, networking and software into a single, integrated system that reduces customers’ lighting-related energy use by up to 90 percent, and transforming industrial lighting into a powerful platform for improved control, efficiency and operational insight. The company is distinguished by breakthrough technology, a management team of proven visionaries from the solid-state lighting and distributed networking industries, and proven results from real-world client deployments.
Eka Systems was acquired by Cooper Industries in April 2010. The company is a global manufacturer and supplier of wireless, self-managing, self-healing Smart Network and Smart Grid networking solutions that provide unrestricted monitoring and control of customer water, electric and gas data; enabling utility companies to create efficient, flexible and highly scalable AMI, AMR, and Distribution Automation solutions while simultaneously enhancing overall customer satisfaction.
JouleX is the leading innovator in sustainable energy management systems for the enterprise. Its flagship solution, the JouleX Energy Manager (JEM), provides the Global 2000 and government agencies with the ability to monitor, analyze and control energy usage for all network-connected devices and systems across the enterprise, including in distributed offices, data centers and facilities. Importantly, JEM works without the use of software agents, dramatically reducing installation time and removing the maintenance burden associated with similar technologies. JEM decreases energy costs by up to 60 percent while ensuring availability and provides robust reporting that enables compliance with emerging carbon monitoring requirements.
JouleX was founded in 2009 and since has been distinguished with recent awards and accolades including Gartner Cool Vendor in Green IT and Sustainability, GE Ecomagination Award, BT Green Economy Success for Future Award and Clean Tech Media Award. The company is headquartered in Atlanta with worldwide offices located in Tokyo, Paris, Munich and Kassel, Germany.
Acquired by PPD in April 2009, Magen BioSciences focuses on improving the health and appearance of human skin. Magen pursues a science-driven approach to identify and develop novel therapeutics to treat a number of large, poorly served dermatological disorders. The company has assembled an outstanding science, investor and management team. The team includes co-founders of Idexx, Immunex, Alnylam, Momenta, Vertex, Biogen and Genzyme.
MicroCHIPS, Inc. is pioneering the next generation of implantable drug delivery and biosensing devices for use in the pharmaceutical and patient monitoring markets. Our proprietary reservoir technologies include both active and passive forms and provide numerous product opportunities for our partners. MicroCHIPS, Inc. is a privately held company headquartered in Bedford, Massachusetts. The Company was founded in 1999 by Dr. John Santini, MIT Professors Michael Cima and Robert Langer, and Terry McGuire of Polaris Venture Partners. Our world-class team of twenty-nine includes the best and brightest scientists and engineers in the fields of drug formulation, biosensor development, materials science and microelectronics.
As an innovator, creator and leading supplier of integrated physician information systems, PatientKeeper's applications provide a single point of anytime, anywhere access to clinical and financial data from multiple, disparate systems. PatientKeeper's technology automates the provider’s day to transform their experience and improve satisfaction. The Company’s physician-centric portal and mobile applications improve user satisfaction and patient safety, increase revenue and simplify data access and interoperability for community health information exchange.
PolyRemedy, Inc. manufactures robotic systems for the fabrication of nano-material based wound dressings at the point-of-care, allowing wound care clinicians to easily and cost-effectively deliver customized wound care on-demand for each patient’s unique wound.
Leveraging its portfolio of patented urinary protein biomarkers and clinical algorithms, Predictive Biosciences is pioneering intervention diagnostic assays for informed cancer management™. The company’s proprietary clinical algorithms, which deliver exceptionally high negative predictive value (NPV) and positive predictive value (PPV), can be applied to significantly enhance the performance of biomarkers and diagnostic assays. Predictive Biosciences is initially focused on diagnostics for the precise management of cancer survivors.
Predilytics, Inc. is an information technology company that provides solutions to the healthcare industry. The company’s first series of products focus on assisting health plans and providers identify and prioritize opportunities against key business initiatives which include improving appropriate documentation for disease burden, attracting and retaining plan membership, enhancing the effectiveness of care management and reducing costly facility admissions/re-admissions. Predilytics utilizes the latest machine learning technology proven in the financial and advertising sectors but not yet leveraged in the healthcare markets.
Acquired by Cell Biosciences in December 2009. Protein Forest, Inc. (founded in 2002) is a proteomics tools company located in Lexington, Massachusetts. The company develops, manufactures and markets instruments, consumables and software products to scientists around the world. The initial product lines utilize a new technology called parallel isoelectric focusing which is incorporated into the digital ProteomeChip™ (dPC™).
Sample6 Technologies is a dynamic startup company at the intersection of breakthroughs in synthetic biology, sensors, and data modeling and visualization. The company’s mission is to improve the health and safety of global consumers by building integrated systems that can quickly and easily detect harmful and unwanted bacteria in the food, healthcare, and other industries.
Sciformix is a US headquartered Knowledge Process Outsourcing company whose aim is to deliver high quality knowledge-based services using a cost-optimized global delivery model. The company delivers specialized services of the highest quality in global Drug Safety Data Management, Clinical Data Management, Biostatistics and Medical Writing. Founded by two experienced professionals, Sciformix's core team comprises of industry experts in drug safety, epidemiology, labeling, biostatistics, and medical affairs. Sciformix management has the unique combination of internal experience in global pharmaceutical companies and building organizations delivering specialized services from India.
SpringLeaf Therapeutics is creating innovative therapeutic modalities to address serious disease and elevate the quality of care for patients. SpringLeaf’s technology is based on the convergence of materials science and medicine and is designed to enable and differentiate therapeutics. SpringLeaf was founded based on breakthrough science at MIT and is backed by leading investors including SR One, Flybridge Capital Partners and North Bridge Venture Partners.
T2 Biosystems is a private biotechnology company developing next-generation medical diagnostic products using its proprietary technology, combining nanotechnology and miniaturized magnetic resonance (MR) technology to provide rapid, accurate and portable diagnostics. T2 Biosystems was founded in 2006 by renowned researchers including Robert Langer, PhD, Michael Cima, PhD and Tyler Jacks, PhD from the Massachusetts Institute of Technology, and Ralph Weissleder, MD and PhD and Lee Josephson, PhD from Massachusetts General Hospital.
TARIS Biomedical Inc., a specialty pharmaceutical company with deep domain expertise in therapeutics and drug-delivery, is focused on local minimally-invasive drug-device convergence products. The TARIS core technology and development efforts are being applied to disease areas with high unmet medical need in which current therapies or systemic treatments have failed. TARIS Biomedical has several drug-device convergence program opportunities focused on addressing those underserved disease areas through local delivery of therapeutics, with an initial focus on bladder diseases including Interstitial Cystitis (IC)/Painful Bladder Syndrome (PBS).